Resource utilisation, costs and clinical outcomes in non-institutionalised patients with Alzheimer’s disease: 18-month UK results from the GERAS observational study

被引：0
|
作者：
Alan Lenox-Smith
Catherine Reed
Jeremie Lebrec
Mark Belger
Roy W. Jones
机构：
[1] Eli Lilly and Company,
[2] Eli Lilly and Company,undefined
[3] Eli Lilly and Company,undefined
[4] RICE (The Research Institute for the Care of Older People),undefined
[5] Royal United Hospital,undefined
来源：
BMC Geriatrics | / 16卷
关键词：
Alzheimer’s disease; Clinical outcomes; Societal costs; AD dementia severity; Resource use; MMSE;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Resource utilisation, costs and clinical outcomes in non-institutionalised patients with Alzheimer's disease: 18-month UK results from the GERAS observational study
    Lenox-Smith, Alan
    Reed, Catherine
    Lebrec, Jeremie
    Belger, Mark
    Jones, Roy W.
    [J]. BMC GERIATRICS, 2016, 16 : 1 - 10
  • [2] COST AND RESOURCE USE IN NON-INSTITUTIONALISED ALZHEIMER'S PATIENTS - RESULTS FROM AN OBSERVATIONAL STUDY IN THE UK OVER 18 MONTHS
    Lenox-Smith, A.
    Reed, C.
    Lebrec, J.
    Belger, M.
    Smyth, A.
    Jones, R. W.
    [J]. AGE AND AGEING, 2015, 44 : i15 - i15
  • [3] Resource Use and Cost of Alzheimer's Disease in France: 18-Month Results from the GERAS Observational Study
    Rapp, Thomas
    Andrieu, Sandrine
    Chartier, Florence
    Deberdt, Walter
    Reed, Catherine
    Belger, Mark
    Vellas, Bruno
    [J]. VALUE IN HEALTH, 2018, 21 (03) : 295 - 303
  • [4] OBSERVATIONAL STUDY OF RESOURCE USE AND COST OF ALZHEIMER'S DISEASE IN EUROPE (GERAS)-18-MONTH RESULTS FROM THE FRENCH COHORT
    Rapp, T.
    Vellas, B.
    Andrieu, S.
    Chartier, F.
    Baraille, L.
    Belger, M.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A409 - A409
  • [5] Costs and resource use of community-dwelling patients with Alzheimer's disease in Japan: 18-month results from the GERAS-J study
    Nakanishi, Miharu
    Igarashi, Ataru
    Ueda, Kaname
    Brnabic, Alan J. M.
    Matsumura, Taka
    Meguro, Kenichi
    Yamada, Masahito
    Mimura, Masaru
    Arai, Heii
    Treuer, Tamas
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (08) : 1331 - 1339
  • [6] Dependence Levels as Interim Clinical Milestones Along the Continuum of Alzheimer's Disease: 18-Month Results from the GERAS Observational Study
    Kahle-Wrobleski, K.
    Andrews, J. S.
    Belger, M.
    Ye, W.
    Gauthier, S.
    Rentz, D. M.
    Galasko, D.
    [J]. JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE, 2017, 4 (02): : 72 - 80
  • [7] Representativeness of European clinical trial populations in mild Alzheimer's disease dementia: a comparison of 18-month outcomes with real-world data from the GERAS observational study
    Reed, Catherine
    Belger, Mark
    Dell'Agnello, Grazia
    Kahle-Wrobleski, Kristin
    Sethuraman, Gopalan
    Hake, Ann
    Raskin, Joel
    Henley, David
    [J]. ALZHEIMERS RESEARCH & THERAPY, 2018, 10
  • [8] Representativeness of European clinical trial populations in mild Alzheimer’s disease dementia: a comparison of 18-month outcomes with real-world data from the GERAS observational study
    Catherine Reed
    Mark Belger
    Grazia Dell’Agnello
    Kristin Kahle-Wrobleski
    Gopalan Sethuraman
    Ann Hake
    Joel Raskin
    David Henley
    [J]. Alzheimer's Research & Therapy, 10
  • [9] Costs associated with Alzheimer's disease in Italy: baseline results from the GERAS II observational study
    Bruti, G.
    Bruno, G.
    Mancini, M.
    Reed, C.
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2016, 52 : S61 - S62
  • [10] COMPARING RESOURCE USE IN ALZHEIMER'S DISEASE ACROSS THREE EUROPEAN COUNTRIES-18-MONTH RESULTS OF THE GERAS STUDY
    Belger, M.
    Arigmon, J. M.
    Dodel, R.
    Haro, J. M.
    Wimo, A.
    Reed, C.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A759 - A760
12345